The Latest on Emerging Therapies for Metastatic HR+/HER2- Breast Cancer ...
22 hours ago · The Latest on Emerging Therapies for Metastatic HR+/HER2- Breast Cancer — Novel weapons to counter endocrine therapy resistance and treat progressive disease
UC Irvine Breast Cancer Clinical Trials — Orange County, CA
Nov 26, 2025 · The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic …
Orange County, CA - UCI Health
Oct 17, 2024 · Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-Label, Multicenter Trial of Oral Zongertinib (BI 1810631) in Combination with …
Enhertu/Perjeta Combo Enhances Quality of in HER2+ Advanced Breast Cancer
18 hours ago · Enhertu and Perjeta led to better quality-of-life and less side effects than standard-of-care among patients with HER2+ advanced or metastatic breast.
Adding Tucatinib to First-line Maintenance Therapy Delayed Disease ...
2 days ago · Based on this, the U.S. Food and Drug Administration approved this drug in 2020 for treatment of unresectable locally advanced or metastatic HER2-positive breast cancer, including …
Abemaciclib Monotherapy Shows Efficacy After CDK4/6 Inhibition in …
1 day ago · Abemaciclib monotherapy displayed a clinical benefit in some patients with HR+/HER2– breast cancer after CDK4/6 inhibitor therapy.
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali ...
2 days ago · Metastatic breast cancer is cancer that has spread beyond the breasts to other parts of the body. Long-term progression-free survival benefit with Kisqali was observed in patients regardless of …
1 in 4 metastatic breast cancer patients treated with - GlobeNewswire
3 days ago · “The latest MONALEESA analysis shows that 1 in 4 patients with metastatic disease remained progression-free for four years or more.
Talzenna For Metastatic Breast Cancer: A Promising Treatment Option At Uci
Treating metastatic breast cancer can be difficult, as it often requires a combination of therapies and ongoing adjustments to treatment plans. Talzenna has been approved for use in patients with HER2 …
UC Irvine Breast Cancer Trial: Tucatinib vs. Placebo in Combination ...
This study is designed to evaluate the efficacy and safety of tucatinib in combination with T-DM1 in participants with unresectable locally-advanced or metastatic HER2+ breast cancer who have had …